BeiGene, Ltd. has entered into exclusive in-licensing and co-development agreements with Janssen Pharmaceutica NV for two clinical-stage oncology compounds. BeiGene will in-license intetumumab (CNTO-95) for clinical development and commercialization in Australia, China, Hong Kong, New Zealand, Korea, Singapore and Taiwan. The two companies will co-develop intetumumab in multiple cancer indications. BeiGene will receive a royalty on global sales outside of these regions. Both parties will share i...